GALAXY BIOTECH

To avoid the high costs and long lead times needed for target discovery, Galaxy selects a limited number of targets that have already been described in the scientific literature but have not been exploited for various reasons, such as difficulty in developing suitable mAbs.Stay focused on research by outlicensing product candidates at the preclinical stage to larger pharmaceutical or biotechnology companies.